Background: The objective of this retrospective study was to determine factors impacting survival among women with inflammatory breast cancer (IBC).
introduction
It is estimated that 207 090 women will be diagnosed with breast cancer in the United States in 2010 and 39 840 deaths will be attributed to this disease [1] . Among women diagnosed with breast cancer, 2.5% will be diagnosed with an aggressive subtype of locally advanced breast cancer (LABC) known as inflammatory breast cancer (IBC) [2] . Due to the rarity of IBC, much of the information known about this disease and its formulated management guidelines has been derived from retrospective studies and extrapolation of results from prospective trials dealing with largely non-IBC breast tumors. The Surveillance, Epidemiology and End Results Registry (SEER) is a large population-based cancer registry that covers 26% of the population in the United States [3] and affords a means of studying patient and tumor characteristics of IBC. Using such population-based data key observations made about IBC include younger age at diagnosis compared with women with non-IBC tumors, a higher risk of IBC observed among African-American women, lower median survival compared with women with non-IBC LABC and an increasing incidence of IBC in the United States [4] .
IBC, a once uniformly fatal disease, when treated with a multidisciplinary approach incorporating preoperative anthracycline-based chemotherapy, surgery and radiation therapy is associated with a median survival of 40 months [5] . The question that arises is whether IBC is uniformly associated with poor prognostic outcome or whether subgroups, similar to those seen in non-IBC tumors, are present that are associated with different survival outcomes? At the molecular level, several studies utilizing small numbers of IBC tumor samples have shown molecular subtypes similar to those observed among women with non-IBC tumors [6] [7] [8] [9] [10] [11] . However, comparisons across studies have been difficult due to variability in case definition [12] . In 2004, SEER implemented the use of the American Joint Committee on Cancer (AJCC) sixth edition, whereby IBC is coded as T4d. The categorization of T4d follows a set of specific criteria and, in general, is defined according to the AJCC [13] as 'a clinicopathologic entity characterized by diffuse erythema and edema (peau d'orange) of the breast, often without an underlying palpable mass'. Using data derived from SEER that uses the AJCC (sixth edition) standard case definition of IBC, the aim of this large retrospective study was to identify patient and tumor characteristics that affect the survival outcomes of women with IBC.
patients and methods

patient population
This retrospective study employed data derived from the National Cancer Institute's limited use SEER 17 registry databases that were released in April 2010. Using this population-based database, we identified patients with stage IIIB/C and IV IBC. Search criteria were restricted to patients who were female and had histologically confirmed invasive carcinoma. Patients with more than one primary cancer were excluded. Furthermore, cases selected were restricted to those diagnosed between 1 January 2004 and 31 December 2007, as during this time period, IBC was coded within SEER according to the AJCC sixth edition [13] . IBC was identified within SEER as T4d disease. Variables recorded included tumor characteristics, age at diagnosis, race, year of diagnosis and marital status.
statistical analysis
Registries participating in the SEER program regularly update follow-up information and vital status for all patients with cancer. Median follow-up time was calculated as the median observed survival time among all women with IBC included in the analysis. Follow-up cut-off was 31 December 2007. Two survival outcomes were computed and estimated using the Kaplan-Meier product-limit method and the log-rank test used to assess for differences between patient groups. Overall survival was computed from the time of diagnosis of IBC to the time of death from any cause or last follow-up with patients still alive at last follow-up censored. Inflammatory breast cancer-specific survival (IBCS) was computed from the time of diagnosis of IBC to the time of death from IBC with patients who died of other causes or still alive at last follow-up censored. Cox models were then fitted to assess the multivariable relationship of various patient and tumor characteristics and the survival outcomes. All models were adjusted for the 17 SEER registries. Cox models were then rerun stratified by stage of IBC to determine prognostic factors associated with each stage (III versus IV). All P values were two-sided and values <0.05 considered to be statistically significant. All analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC). Table 2 summarizes the 2-year IBCS and overall survival estimates. At the time of the analysis, 796 (33.4%) women had died of all causes and 684 (28.7%) women had died from IBC. Median follow-up was 15 months (range 0-47 months). Two-year overall survival and IBCS for the whole cohort was 63% [95% confidence interval (CI) 60% to 65%] and 69% (95% CI 64% to 69%), respectively. Two-year IBCS among women with stage IIIB, IIIC and IV disease was 81% (95% CI 78% to 83%), 67% (95% CI 60% to 73%) and 42% (95% CI 38% to 47%), respectively, with the difference across the three groups being statistically significant (P < 0.0001). In the univariate analysis, factors found to be significantly associated with improved survival outcome included positive hormonal receptor status, younger age at diagnosis, having surgery, having radiation therapy to the primary site, having low-grade tumors ( Figure 1 ). multivariable models Table 3 summarizes the multivariable Cox models for IBCS and overall survival for the whole cohort. After adjusting for a number of patient and tumor characteristics, women with stage IIIB disease and those with stage IIIC disease had a 63% [hazard ratio (HR) 0.373, 95% CI 0.296-0.470, P < 0.001] and 31% (HR 0.691, 95% CI 0.512-0.933, P = 0.016) decreased risk of death from IBC, respectively, compared with women with stage IV disease that was statistically significant. Compared with women who were of white/other race, those who were of black race had a 55% increased risk of death from IBC, with the difference being statistically significant (HR 1.552, 95% CI 1.193-2.019, P = 0.0011). Table 4 summarizes the multivariable Cox models for IBCS stratified by stage of disease. Among women with stage III disease, factors significantly associated with decreased risk of death from IBC included stage IIIB disease, low-grade tumors, being of white/other race, undergoing surgery, receiving radiation therapy and hormone receptor-positive disease. Among women with stage IV disease, factors significantly associated with decreased of death from IBC included lowgrade tumors, younger age at diagnosis and hormone receptorpositive disease. Furthermore, among women with stage IV disease, those who underwent surgery of their breast primary had a 51% decreased risk of death compared with those who did not undergo surgery and this was statistically significant (HR = 0.489, 95% CI 0.339-0.704, P < 0.0001).
discussion
The aim of this retrospective study was to identify patient and tumor characteristics that differentially affect the survival outcome of women with IBC. In this large retrospective study, we show that lower stage of disease, low-grade tumors, receiving local therapy (surgery and radiation therapy), being of white/other race and having hormone receptor-positive disease were all associated with improved prognostic outcome among women with IBC.
Our understanding of breast cancer biology over the past decade has significantly improved with the most important survival reported as 60% in the basal subtype, 19% in the HER2-overexpressing subtype and 73% in the luminal A subtype (P = 0.08). In our large population study, we are able to show that among women with IBC, 2-year breast cancerspecific survival was 80% and 50% among those with hormone receptor-positive and -negative disease, respectively (P < 0.0001). This difference was observed among both women with stage III and IV IBC. The group from the Royal Marsden hospital reported a similar differential prognostic outcome, albeit among a much smaller cohort of women with IBC [17] . Unfortunately, SEER does not currently record HER2 status and we were thus not able to look at this variable. However, interestingly, several groups have shown that HER2 status of IBC tumors in the absence of exposure to trastuzumab does not have an associated adverse prognostic impact [18, 19] . In the presence of trastuzumab, however, HER2 status appears to confer a good prognostic outcome among women with IBC [19, 20] . The concept of removing the primary tumor among women with stage IV breast cancer is a controversial one. Numerous retrospective studies have evaluated the role of local treatment of the primary tumor among women with de novo stage IV breast cancer [21] [22] [23] [24] [25] [26] . One such study comes from the MD Anderson Cancer Center. The investigators [22] looked at a cohort of 75 women with de novo stage IV breast cancer who had undergone surgery of their primary tumor. The investigators reported an improved metastatic progression-free survival among women who had undergone surgical extirpation of their primary tumor >3 months after diagnosis. Similar results in improvement in outcome have been reported by other investigators, although all reports have been thus far retrospective in nature and subject to both selection and publication bias. Despite the lack of confirmatory randomized data to support the notion of survival benefit, most series report 37%-61% of women with de novo stage IV breast cancer undergoing surgery of their primary tumor. In our study, we show that among women with de novo stage IV IBC, those that underwent surgery directed to their affected breast had a 51% decreased risk of death from IBC compared with those who did not undergo surgery (P < 0.0001). This translated into an absolute difference of 25% in 2-year IBCS favoring the group of patients who underwent surgery of their primary ( Figure 2 ). These results are intriguing and lend support to the data described for de novo stage IV non-IBC tumors. However, the results should be viewed with caution, as it is likely that women with de novo stage IV IBC undergoing surgery to their affected breast are those with limited metastatic disease and those that show good response to systemic therapy. Unfortunately, SEER at this time does not code for these factors.
In summary, in this large population-based study, we show that there are a number of patient and tumor characteristics that affect outcome of women with IBC. This study is subject to all the biases that are generally associated with any retrospective population-based study. Furthermore, an important limitation of the study was the fact that we were unable to attain information on systemic treatment received and HER2 status of tumors both of which are not coded within the SEER registry. Despite these limitations, the results obtained generate a number of important conclusions. First, although IBC is an aggressive phenotype of breast cancer, similar to non-IBC tumors, it is also a heterogeneous disease with various defined subgroups associated with differential prognostic outcome. Second, with the recognition that IBC is across the board associated with worse prognostic outcome than non-IBC tumors, and the fact that several patient and tumor factors affect survival of women with IBC, nomograms will need to be developed to specifically target this patient population. Currently, Adjuvant! Online, an invaluable tool to discuss outcomes in the clinic, does not address prognostic outcomes of women with IBC. Third, within the caveats of this study, it appears that surgery of the primary tumor among women with de novo stage IV IBC is associated with an improved prognostic outcome, indicating that aggressive treatment both with systemic and local therapy may be indicated in carefully selected groups of women with de novo stage IV IBC.
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